SOST and plasma cell myeloma: This highlights the potential for combining anti‐LRP6 with other Wnt‐targeted soluble antagonists, such as the potent bone anabolic anti‐SOST (romosozumab), or even the dual anti‐SOST/DKK1 antibody,(18) to provide even greater protection against myeloma‐induced bone disease.